Clinical Trial Update: Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial investigating solifenacin succinate for urinary toxicity during radiotherapy for prostate cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Solifenacin succinate (solifenacin)

Snippet

Sponsor: Center Eugene Marquis | Conditions: Overactive Bladder | Phase 3 | Status: TERMINATED